The global Age-related Macular Degeneration (AMD) drugs market is undergoing a pivotal transformation. Valued at US$9.55 billion in 2023, it is forecasted to reach US$17.37 billion by 2029, expanding at a robust CAGR of 10.7%. This upward trajectory is not only driven by the rising prevalence of AMD but also by groundbreaking advancements in ophthalmology drugs, favorable reimbursement policies, and accelerated R&D programs.
For C-level executives operating in the pharmaceutical, biotech, and investment sectors, understanding the dynamics of this market is crucial to identifying high-ROI opportunities and navigating evolving patient demands.
What’s Fueling Growth in the AMD Drugs Market?
1. Surge in AMD Incidence
A growing aging population and shifts in lifestyle habits—such as increased smoking, alcohol consumption, poor diet, and sedentary behavior—are fueling AMD prevalence. With over 200,000 new AMD cases reported annually in the U.S. alone, the demand for both wet & dry AMD drugs is expected to rise significantly.
2. Rapid Drug Development and Regulatory Support
Pharmaceutical and biotechnology companies are leveraging fast-track approvals from regulatory bodies like the U.S. FDA to accelerate the commercialization of novel ophthalmology drugs. Notably, OPT-302 by Opthea (Australia) received fast-track status for treating wet AMD in 2021. Similarly, Merck & Co.’s 2024 acquisition of EyeBio has added a promising Phase 2 AMD candidate to its portfolio.
3. Policy Reforms and Reimbursement Improvements
Expanding access to therapeutic ophthalmology drugs through enhanced reimbursement models has boosted patient affordability, especially in developed economies like the U.S., UK, and Germany. This policy momentum is translating into broader drug adoption and treatment continuity.
Why Is Off-Label Use a Concern for the Market?
Despite advancements, the high cost of AMD drugs—particularly anti-VEGF therapies like Eylea and Vabysmo—has led to the widespread off-label use of Avastin (Bevacizumab). Though not originally developed for AMD, Avastin offers similar efficacy at a fraction of the cost.
This practice has significantly impacted the commercial uptake of FDA-approved AMD drugs. In fact, Avastin accounts for nearly 50% of the wet AMD market by volume, with insurance coverage backing its use in countries like the U.S., UK, and Italy. While this enhances patient access, it poses a competitive challenge to branded wet AMD drugs developers and reduces potential market revenue.
Where Are the Breakthrough Opportunities?
1. Emerging Drug Modalities
Current therapies rely on monoclonal antibodies and fusion proteins, which require frequent intravitreal injections—leading to patient dropouts and adherence issues. To counter this, R&D is now pivoting toward innovative modalities:
- Gene therapy: Companies like Adverum Biotechnologies are working on single-dose, long-term treatments for wet AMD.
- Eye drop formulations: Researchers at the University of Illinois developed an allosteric inhibitor of EB3 protein in 2023, designed as eye drops to treat wet AMD.
- Hydrogels and oral inhibitors: New delivery mechanisms are being explored to eliminate the discomfort and cost of repeated injections.
These advancements aim to improve patient convenience and reduce the economic burden—making them high-value opportunities for investors and executive decision-makers.
2. Growth in Developing Markets
Regions in Asia Pacific, Latin America, and Eastern Europe are witnessing rapid urbanization, lifestyle shifts, and increased healthcare spending. These markets offer first-mover advantages for companies introducing cost-effective dry AMD drugs and biosimilars.
For example, Sandoz’s biosimilar, Enzeevu, was recently approved in the U.S. for wet AMD treatment and could serve as a model for emerging-market rollouts.
Who Are the Key Players in the AMD Drug Ecosystem?
The AMD drugs market ecosystem is multifaceted, involving:
- Pharmaceutical giants: Regeneron, Novartis, Roche, Bayer, Merck & Co.
- Biotech innovators: Adverum, Kodiak Sciences, Opthea
- Academic and research institutions: Driving early-stage molecule discovery
- Regulatory authorities: Ensuring safety and compliance
- Payers and insurance providers: Influencing drug accessibility and pricing
Collaborations among these stakeholders are essential to streamline discovery, optimize clinical trials, and expand access to both wet & dry AMD drugs.
When Should Executives Act?
The window for competitive advantage is now. With rising disease incidence and evolving treatment expectations, first-mover innovation, IP protection, and market access strategies will be critical differentiators. C-suite leaders should:
- Accelerate investment in new modalities such as gene therapies and non-invasive delivery systems.
- Explore strategic M&A to gain access to late-stage pipeline assets.
- Leverage data analytics for better clinical outcomes and regulatory submissions.
- Target emerging economies with biosimilars and price-sensitive treatment plans.
Final Takeaway: How Can Executives Maximize ROI?
To fully capitalize on the expanding ophthalmology drugs market, particularly in AMD, executives must align their strategies with patient needs, policy trends, and innovation timelines. The future of wet & dry AMD drugs lies in affordability, accessibility, and reduced treatment burdens—areas ripe for disruption.
Companies that act decisively on these fronts are best positioned to lead in market share, reputation, and long-term shareholder value.
For more information, Inquire Now!
